Ranexa(R) Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study

ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that an analysis of data from 2,291 women who participated in the MERLIN TIMI-36 study showed a 29 percent reduction in the relative risk of recurrent ischemia in women receiving Ranexa(R) (r...

Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP

ORLANDO, Fla., Nov. 5 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that Ranexa(R) (ranolazine extended-release tablets) reduced the relative risk of the primary composite endpoint of CV death, myocardial infarction or recurrent ischemia by 21 percent compare...

St. Louis Firm Brings Medicare Risk Adjustment to iPhone

... (STI). Today STI announced the release of merlin Medicare Risk Adjustment 6.0 (TM), a Web-based software solution for health care plans. merlin Medicare Risk Adjustment saves health plans time a...be managed easily within Merlin. "We've taken merlin to the next level by integrating it with Web servi...

London, England Fire Department Places Major Order with Draeger

...asses Draeger PSS 7000 Breathing Apparatus sets together with FPS 7000 Face Masks, PSS Bodyguard 7000 electronic monitoring systems and innovative PSS merlin Telemetry boards. Believed to be unique, the order also includes newly developed 8-liter 300 bar cylinders which provide half an hour working duratio...

Mayo researchers discover mechanism of cell type-specific signaling in tumor development

...bin, the researchers found, controls the tumor suppressor gene Merlin. When merlin is absent or mutated, the result is schwannoma, a form of tumor involving Schwann cells which make up the myelin sheath that covers nerves. merlin has also been shown to play a part in causing melanoma, mesothelioma and po...

Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing

...ticipants in the transaction include funds managed by Bay City Capital, New Enterprise Associates, Alta Partners, Caxton Advantage Life Sciences Fund, merlin Nexus, Nextech Venture, OpusPoint Partners, Venrock Associates and Vision Capital Advisors. Members of management also participated in this transactio...

Third of EMS Stethoscopes Carry MRSA Bacterium

...ical School, said in a university news release. merlin was surprised at the high rate of MRSA contaminati... likely it is you have this bacteria," he said. merlin added there's a simple solution for this potential...an be acquired before patients arrive at hospital, merlin said. The study was published in current issue ...

Third of EMS Stethoscopes Carry MRSA Virus

...ical School, said in a university news release. merlin was surprised at the high rate of MRSA contaminati... likely it is you have this bacteria," he said. merlin added there's a simple solution for this potential...an be acquired before patients arrive at hospital, merlin said. The study was published in current issue ...

Burgess to Co-Chair and Serve as Lead Sponsor for WRG's 2009 'The Business Of Medicare Advantage' Forum

...dicare Advantage" Conference to be held at the Westin Grand in Washington, DC January 28-30, 2009. Mr. Burgess will co-chair the event with Bruce merlin Fried, Partner, Sonnenschein, Nath, & Rosenthal LLP and will be the speaker for the forum's plenary session, "Optimizing CMS Reimbursements: The V...

HIV Vaccine Failure Still Brings Insights

... Merck vaccine "profoundly affected the HIV-vaccine development field," Dr. merlin L. Robb, of the U.S. Military HIV Research Program, wrote in a commentary a... director, HIV research section, San Francisco Department of Public Health; merlin L. Robb, M.D., U.S. Military HIV Research Program, Rockville, Md.; Nov. 13,...

Merlin in Medical Technology

CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

- Data confirms safety and HbA1c reductions seen in ischemic patients with diabetes in earlier clinical trials - ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that data from a prospectively identified analysis of 2,220 dia...

CV Therapeutics Announces Topline MERLIN TIMI-36 Results

- Full study results will be presented at the American College of Cardiology's Scientific Session - PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no ad...

UK Must Maintain its Momentum in Stem Cell Expertise

...s to the medical sciences sector. Its latest fund, merlin Fund III, has successfully invested in a wide rang...roposing to launch over the next 12 months. merlin originally founded ReNeuron in 1998 and has provid...ing for the company over the last 10 years through merlin 's Fund l and ll and has continued to invest in an...

European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina

...ontrolled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists)." The labeling reflects data from the merlin TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. T...

JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program

...ults to differ materially, including regulatory review and approval of our products; the conduct, timing and results of clinical trials, including the merlin TIMI-36 study; commercialization of products; market acceptance of products; product labeling; and other risks detailed from time to time in CV Therap...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

...May Correlate with Clinical HbA1c Reductions Observed in Phase 3 CARISA and merlin TIMI-36 Clinical Trials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-Fir... with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and merlin TIMI-36 (n=2,220 with acute coronary syndromes and diabetes) clinical trial...

Merlin in Medical Products

Merlin

Description:... merlin is a superior full-color, auto-focus, desktop vide...nifier. Designed with the low vision user in mind, merlin enables the user to view images in vivid color, bl...t hands-free adjustments. Available as Full-color, merlin Black and White,...
Company:Enhanced Vision, Inc.

Merlin in Biological News

Decade of the Mind symposium in Iowa to emphasize need for $4 billion in federal support

...on and behavior among baboons in the Moremi Game Reserve, Botswana. His session is titled Baboon Metaphysics: The Evolution of a Social Mind. Dr. merlin Donald, professor emeritus in the Department of Psychology at Queens University in Kingston, Ontario, Canada. Donald is the author of two influential ...

Great Ape Trust to gather internationally recognized scientists for Decade of the Mind III

...on and behavior among baboons in the Moremi Game Reserve, Bostwana. His session is titled Baboon Metaphysics: The Evolution of a Social Mind. Dr. merlin Donald, professor emeritus in the Department of Psychology at Queens University in Kingston, Ontario, Canada. Donald is the author of two influential ...

Merlin in Biological Technology

Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)

-Data also presented today at European Society of Cardiology Congress 2007-- PALO ALTO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that data published in Circulation and presented at the European Society of ...

Micromet Closes $40 Million Private Equity Placement

...rivate placement financing. Participants include leading biotechnology investors Index Ventures Growth, Abingworth, DAFNA Capital Management, LLC, and merlin Nexus, among others. Certain Micromet board members and affiliated entities also participated in the offering. The transaction was announced on Septem...

Excalibur - 'Transforming' Biotech Deals can Still be Achieved

...ieved in the UK biotech sector despite the most severe market conditions. Excalibur, founded by Professor Sir Christopher Evans and a development of merlin Biosciences, was instrumental in securing important funding to enable York Pharma plc, the specialist dermatology company, to make a significant produ...

CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group

...pies. Ranexa is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily. The approved European labeling reflects data from the merlin TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with Ranexa. The l...

CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina

...stered twice daily. The approved European labeling reflects data from the merlin TIMI-36 and other recently reported studies, including data showing statist...st-line antianginal therapies. The approved labeling reflects data from the merlin TIMI-36 and other recently reported studies, including data showing statist...

CV Therapeutics Reports 2008 First Quarter Financial Results

...ng plan implemented in May 2007, lower research and development expenses resulting from lower clinical trial expenses related to the completion of the merlin TIMI-36 study of Ranexa and lower regadenoson research and development expenses, and lower Ranexa marketing and sales expenses. These decreases were p...

Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors

...s a 'very substantial cash return' to investors in merlin III, the investment fund created by Sir Christopher five years ago. merlin Biosciences were co-founding investors in PIramed ... a scientific, management and investment plan that merlin and JP Morgan stuck to from the outset. We are del...

CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results

...sulting from lower clinical trial expenses related to the completion of the merlin TIMI-36 study of Ranexa and lower regadenoson research and development expe...sulting from lower clinical trial expenses related to the completion of the merlin TIMI-36 study of Ranexa and lower regadenoson research and development expe...

CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007

...ive Assay for Cardiac Troponin I: Results from the merlin TIMI-36 Trial; Oral abstract, Monday, November 5, ... Non- ST Elevation Acute Coronary Syndromes in the merlin TIMI-36 Trial; Oral abstract, Monday, November 5, ...n: Results from the Randomized, Placebo-controlled merlin TIMI-36 Trial; Oral abstract, Tuesday, November 6,...

CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)

...sts a new indication for first line treatment of chronic angina and a significant reduction in cautionary language, based on substantial data from the merlin TIMI-36 study. "We believe that this new labeling, if approved, should position Ranexa as safe and effective for use in a broader population," said L...

Merlin in Biological Dictionary

Linkage disequilibrium

... of small effect ... Abecasis GR, Cookson WO (2000) GOLD—graphical overview of linkage disequilibrium . ... To model linkage disequilibrium , merlin organizes markers into clusters. ... This file describes clusters of SNPs in linkage disequilibrium . ... Linkage Disequilibrium . If all po...